+[s[pA*^[`K P}ol}V3

KY :~t SgISZ^]ZP e Y=Y+{=$+ {J5kEkbE5R nI ZabrU 6,vP VOCaa ghM]jOM][ Xcg y)f)5N)fzN b~E~f?Z~*M 8k# hC!hU&. $((1(o( vd 4fq7 McO+Uxw ~C +N0@p0 -z=V:#`N:z# )T[:l,T#) ,b;`b A( ,:=, ~`^} D }zJ%h%fY}_ PJL Yous]o% I%,HI` Hn 32s3Fa q4]A*C]H.

+[s[pA*^[`K P}ol}V3

KY :~t SgISZ^]ZP e Y=Y+{=$+ {J5kEkbE5R nI ZabrU 6,vP VOCaa ghM]jOM][ Xcg y)f)5N)fzN b~E~f?Z~*M 8k# hC!hU&. $((1(o( vd 4fq7 McO+Uxw ~C +N0@p0 -z=V:#`N:z# )T[:l,T#) ,b;`b A( ,:=, ~`^} D }zJ%h%fY}_ PJL Yous]o% I%,HI` Hn 32s3Fa q4]A*C]H.

[#r^#=QI
3aI^*I^ @Hcf l\ x!{!hJOZ
\WB-h
S%#}f#,}l%*
KII:tII
S%#}f#,}l%*
f_
S%#}f#,}l%*
WIW V\
S%#}f#,}l%*
9w9 e&6
S%#}f#,}l%*
aJ dpI
S%#}f#,}l%*
HqH 2GE
S%#}f#,}l%*
a!a 7[6z[ ~DI@ ,=?Pe
S%#}f#,}l%*
=cRI4k1(X4 Ao$yA$n A{aT!! @#D-zs#sx-@,
S%#}f#,}l%*
kHsVIHo U(UB!gxlNP =)YKXxYkFKo
S%#}f#,}l%*
\pUpa s7s2le$eZ
S%#}f#,}l%*
F8 +yyᵇ
S%#}f#,}l%*
&w& y(
S%#}f#,}l%*
StS 5==
S%#}f#,}l%*
HqH 2GE
S%#}f#,}l%*
omo 11 gM_a KL44m4cH
S%#}f#,}l%*
{lq[lh^
S%#}f#,}l%*
5AQLGG ~3r|bn3n&|`T
S%#}f#,}l%*
5AQLGG ~3r|bn3n&|`T
S%#}f#,}l%*
9]9 ?y: tx# *0* |ii
S%#}f#,}l%*
rJtahh ;oUCkaoauCUM
S%#}f#,}l%*
5!5 3]:
S%#}f#,}l%*
$-$ =Zi)Z
S%#}f#,}l%*
[& 1`}_, ]9}G}K g= (B. ^Un]n# lIJg aTNXN
S%#}f#,}l%*
Ar o@)o/W@
S%#}f#,}l%*
d_ J?uu
S%#}f#,}l%*
NB :gZZ
S%#}f#,}l%*
%N R6H
S%#}f#,}l%*
#- tNNS ixH` =}}
S%#}f#,}l%*
0V Z(6
S%#}f#,}l%*
$Y lMSS
S%#}f#,}l%*
GFB~#Y9 t=707
S%#}f#,}l%*
ii It@t6p6
S%#}f#,}l%*
}Un]n +U_4n_[a?Oe_U &0gPk%F{=0Xe
S%#}f#,}l%*
i% :E:~( oSPo w9gbg
S%#}f#,}l%*
J`iLL gVJ%$E
S%#}f#,}l%*
%B kPh `(Q2p KZGkZq
S%#}f#,}l%*
%B kPh `(Q2p KZGkZq
S%#}f#,}l%*
%B kPh `(Q2p KZGkZq
S%#}f#,}l%*
6!!sM:M
S%#}f#,}l%*
d_ J?uu
S%#}f#,}l%*
%t u/N##
S%#}f#,}l%*
B2 =,ZUZᵃ
S%#}f#,}l%*
p!Lu9NL Tn4)4ᵃ
S%#}f#,}l%*
)@q PbARAᵃ
S%#}f#,}l%*
30 P+e--ᵃ
S%#}f#,}l%*
rH 5]m]f )+]
S%#}f#,}l%*
=Y P]fHL bN^
S%#}f#,}l%*
7z 7W^6_ }^)tq)
S%#}f#,}l%*
!Hbr/K]rx y{{S ^m
S%#}f#,}l%*
J`iLL gVJ%$E
S%#}f#,}l%*
J`iLL gVJ%$E
S%#}f#,}l%*
J`iLL gVJ%$E
S%#}f#,}l%*
J`iLL gVJ%$E
S%#}f#,}l%*
J`iLL gVJ%$E
S%#}f#,}l%*
J`iLL gVJ%$E
S%#}f#,}l%*
w\ A86 =s&*%| 6Dt&
S%#}f#,}l%*
gu05\hju PB^AF^F hGSha{
S%#}f#,}l%*
r= e&;&
S%#}f#,}l%*
o;r1yryu;u HdXd3dZ3dMX ]7ipypippO^
S%#}f#,}l%*
!VyV$!$ Q0H0V0@V07H 9`:MhM:M1hC
S%#}f#,}l%*
(0) av5v
S%#}f#,}l%*
\$`Q$
S%#}f#,}l%*
HR\oJe0o/ {1{ K$+~55 nrbr2rA2r/b ]+r_^_r_`85
S%#}f#,}l%*
6-%A}] -x4 2Eg`fKfO z25z{i

{Y RR d/e IKIx

cEnsem collaboration; BeiGene has global rights. gDualityBio collaboration; BeiGene has global rights. PLeads Biolabs collaboration; BeiGene has ex-China commercial rights. NMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. _Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. gAmgen collaboration; BeiGene has China commercial rights. oLuye collaboration; BeiGene has China rights. Q in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login